THREE UNIQUE AMPLATZERTM VASCULAR PLUG DESIGNS
Learn about each device’s specialized design and use. Watch the product demonstrations below to see how each is prepared, delivered and can be repositioned for precise placement.
SHORT LANDING ZONE EMBOLIZATION: AMPLATZERTM VASCULAR PLUG
With its single lobe and single-layer mesh, the AMPLATZERTM Vascular Plug (AVP) is designed for precise positioning in short landing zones. Its finely braided Nitinol wire mesh provides a high radial force that secures the AVP within the vessel.
VARIABLE LANDING ZONE EMBOLIZATION: AMPLATZER™ VASCULAR PLUG II
The multilayered, multisegmented design of the AMPLATZERTM Vascular Plug II (AVP II) significantly reduces the time to occlusion1 for transcatheter embolization procedures, while allowing you to maintain complete control during positioning and delivery. This self-expanding device provides full cross-sectional vessel coverage which minimizes migration and recanalization potential.1
The AVP II features multilayered mesh lobes which create six occlusive planes for rapid vessel occlusion.1 The device is available in an array of sizes (3-22 mm) for a wide range of vessel diameters.
LOW-PROFILE EMBOLIZATION: AMPLATZER™ VASCULAR PLUG 4
The AMPLATZERTM Vascular Plug 4 (AVP 4) is delivered through a 0.038 inch diagnostic catheter, eliminating the need for catheter exchange. The flexible mesh and floppy distal section of the delivery wire enable the AVP 4 to travel through tortuous anatomy with ease. The device’s low-profile design extends its reach to distal vasculature. Its multilayered, double-lobed design provides rapid2 embolization.
SIZES3 OF VARIOUS VEINS AND ARTERIES
1. Hahn RT, Pibarot P, Stewart WJ, et al. Comparison of transcatheter and surgical aortic valve replacement in severe aortic stenosis: a longitudinal study of echocardiography parameters in cohort A of the PARTNER trial (Placement of Aortic Transcatheter Valves. J Am Coll Cardiol. 2013;61(25):2514-2521.
2. Reardon MJ, Adams DH, Kleiman NS, et al. 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol. 2015;66(2):113-121.
3. Pibarot P, Weissman NJ, Stewart WJ, et al. Incidence and sequelae of prosthesis-patient mismatch in transcatheter versus surgical valve replacement in high-risk patients with severe aortic stenosis: a PARTNER trial cohort-A analysis. J Am Coll Cardiol. 2014;64(13):1323-1334.
4. Zorn GL III, Little SH, Tadros P, et al. Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: a randomized trial of a self-expanding prosthesis. J Thorac Cardiovasc Surg. 2016;151(4):1014-1023.e.3.
5. Trifecta valve [package insert]. Chicago, IL: Abbott; table 9.
6. Carpentier-Edwards Perimount Magna Ease aortic heart valve [package insert]. Irvine, CA: Edwards Lifesciences; table 7.
7. Edwards pericardial aortic bioprosthesis [package insert for Resilia valve]. Irvine, CA: Edwards Lifesciences; table 9.
8. Avalus bioprosthesis [package insert]. Minneapolis, MN: Medtronic; table 8.
9. Intuity Elite valve system [package insert]. Irvine, CA: Edwards Lifesciences; table 13.6.
10. Perceval sutureless heart valve [package insert]. London, UK: LivaNova; table 12.